To evaluate the reliability and application of GeneSearch(TM) breast lymph node assay (Genesearch), a real-time fluorescence quatitative PCR method, in intraoperative assay of metastasis in sentinel lymph nodes (SLNs) from breast cancer patients.Totally 140 SLNs from 80 patients with breast carcinoma were prospectively studied from May 2010 to August 2010. The 80 patients included 78 women and 2 men who ranged in age from 29 to 85 years, and the median age is 49 years. The expression of CK19 and mammaglobulin in all 140 SLNs were detected by Genesearch, and the results were compared with that of histological evaluation of both frozen and paraffin-embedded sections.Among SLNs, by histological analyses, there were 121 without metastasis, 17 w...
The one-step nucleic acid amplification (OSNA) method is an increasingly used procedure for intraope...
Staging by sentinel node (SN) biopsy is the standard procedure for clinically node-negative breast c...
Aims Treatment strategies for breast cancer continue to evolve. No uniformity exists in the UK fo...
Molecular assays are a new and invaluable tool in the assessment of axillary lymph node status and m...
Sentinel lymph node (SLN) status is highly predictive of overall axillary lymph node involvement in ...
Background. Intra-operative assessment is not routinely performed in the UK due to poor sensitivity ...
To determine the performance of intraoperative one-step nucleic acid amplification (OSNA) assay in d...
Nodal status is one of the most important prognostic factors in breast cancer. Established tests suc...
International audienceThe purpose of this prospective multicenter study was to assess one-step nucle...
The aim of the study was to assess the accuracy of a real-time quantitative RT-PCR (qRT-PCR) assay f...
Background: Sentinel lymph node biopsy (SLNB) reduces the morbidity of axillary clearance and is the...
OBJECTIVE: To analyze a procedure for breast cancer that requires performance of a molecular test be...
Aims: Sentinel lymph node (SLN) biopsy is the preferred surgical technique for staging the axilla in...
BACKGROUND: The authors prospectively evaluated the performance of a proprietary molecular testing p...
Background: To validate the clinical value of the One-Step Nucleic Acid Amplification (OSNA) Breast ...
The one-step nucleic acid amplification (OSNA) method is an increasingly used procedure for intraope...
Staging by sentinel node (SN) biopsy is the standard procedure for clinically node-negative breast c...
Aims Treatment strategies for breast cancer continue to evolve. No uniformity exists in the UK fo...
Molecular assays are a new and invaluable tool in the assessment of axillary lymph node status and m...
Sentinel lymph node (SLN) status is highly predictive of overall axillary lymph node involvement in ...
Background. Intra-operative assessment is not routinely performed in the UK due to poor sensitivity ...
To determine the performance of intraoperative one-step nucleic acid amplification (OSNA) assay in d...
Nodal status is one of the most important prognostic factors in breast cancer. Established tests suc...
International audienceThe purpose of this prospective multicenter study was to assess one-step nucle...
The aim of the study was to assess the accuracy of a real-time quantitative RT-PCR (qRT-PCR) assay f...
Background: Sentinel lymph node biopsy (SLNB) reduces the morbidity of axillary clearance and is the...
OBJECTIVE: To analyze a procedure for breast cancer that requires performance of a molecular test be...
Aims: Sentinel lymph node (SLN) biopsy is the preferred surgical technique for staging the axilla in...
BACKGROUND: The authors prospectively evaluated the performance of a proprietary molecular testing p...
Background: To validate the clinical value of the One-Step Nucleic Acid Amplification (OSNA) Breast ...
The one-step nucleic acid amplification (OSNA) method is an increasingly used procedure for intraope...
Staging by sentinel node (SN) biopsy is the standard procedure for clinically node-negative breast c...
Aims Treatment strategies for breast cancer continue to evolve. No uniformity exists in the UK fo...